Showing 2701-2710 of 9110 results for "".
Talking to Patients: Men v. Women
https://practicaldermatology.com/topics/practice-management/talking-to-patients-men-v-women/18693/Every patient is unique, but aesthetic physicians may need to tailor their communication style based on the patient's sex. It's also essential to convey to men that you understand the male aesthetic and how their treatment goals may differ from the typical woman's.Tips on Expanding Your Practice Focus to Men
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/tips-on-expanding-your-practice-focus-to-men/18699/“I see the male patient as a huge opportunity I think men have been largely overlooked,” says Terrence Keaney, MD. He explains what procedures and services appeal to men, talks about the fundamentals of building a male-friendly practice, and offers tips to make male patients more comfortable undergoTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?In-Office Photos Are an Indispensable Benefit According to Joel Schlessinger MD
https://practicaldermatology.com/topics/practice-management/in-office-photos-are-an-indispensable-benefit-according-to-joel-schlessinger-md-/19221/One way dermatologists can chart the success of their patients is by taking photos before, after and during their treatments. For over 20 years, Joel Schlessinger MD has incorporated photos of his patients into his practice. In this video, he describes the benefits of this technique. Joel SchlessVitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.Differentiating GPP From Plaque Psoriasis for Targeted Therapy
https://practicaldermatology.com/issues/august-2025/differentiating-gpp-from-plaque-psoriasis-for-targeted-therapy/36700/While all types of psoriasis carry significant burdens of disease for patients, certain subtypes have more severe symptoms and require more urgency in diagnosis and treatment. Generalized pustular psoriasis (GPP) is one such subtype and may be considered a disease entity with a classification of itsNoah Worcester 2024: Dr. Brodell on Microscopes
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-brodell-microscopes/24579/Robert Brodell, MD, summarizes his lecture on Santa Cruz Antique Microscope Collection at the 2024 Noah Worcester Dermatological Society meeting.Julie Harper, MD, Reacts to New Report on Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/julie-harper-md-reacts-new-report-acne-products-benzoyl-peroxide-bpo/24172/In this video, Julie Harper, MD, a dermatologist with the Dermatology and Skin Care Center of Birmingham, AL, provides her thoughts on the recent Valisure report showing that some common acne products with benzoyl peroxide (BPO) may contain benzene. She says she’s been an “avid prescriber” of acne pAchieve Skin Tightening in 1-2-3
https://practicaldermatology.com/conferences/maui-derm-2024/achieve-skin-tightening-in-1-2-3/20239/Mitchel P. Goldman, MD, Founder and Medical Director, Cosmetic Laser Dermatology, and Medical Director, Platinum Dermatology Partners, explains the three basic technologies he swears by to tighten skin.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.